SCHEMBL29464962

SCHEMBL29464962

Cc1c(F)cccc1-c1nc(NS(=O)(=O)c2cccc(N3CCCC(C)(C(=O)O)C3)n2)ccc1C(F)(F)F

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.33
RORC P51449 1/20 0.33
SCN9A Q15858 1/20 0.33
EIF2AK4 Q9P2K8 1/20 0.32
BTK Q06187 2/20 0.32
KIF18A Q8NI77 4/20 0.31
GHSR Q92847 1/20 0.31
GALR2 O43603 1/20 0.31
GALR1 P47211 1/20 0.31
SCN1A P35498 1/20 0.30
SCN8A Q9UQD0 1/20 0.30
HCRTR1 O43613 1/20 0.30
HCRTR2 O43614 1/20 0.30
PIM1 P11309 1/20 0.30
ABL1 P00519 1/20 0.30
LRRK2 Q5S007 1/20 0.30
RBP4 P02753 1/20 0.30
TTR P02766 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29464935 1.00 KMO (0.33) KMORORCSCN9AEIF2AK4BTK
SCHEMBL19927744 1.00 KMO (0.33) KMORORCSCN9AEIF2AK4BTK
SCHEMBL19951410 1.00 KMO (0.33) KMORORCSCN9AEIF2AK4BTK
SCHEMBL29464931 1.00 KMO (0.33) KMORORCSCN9AEIF2AK4BTK
SCHEMBL19925137 1.00 KMO (0.33) KMORORCSCN9AEIF2AK4BTK
SCHEMBL19927756 0.91 SCN9A (0.33) RORCSCN9AEIF2AK4BTKKIF18A
SCHEMBL29464399 0.91 SCN9A (0.33) RORCSCN9AEIF2AK4BTKKIF18A
SCHEMBL29464499 0.91 SCN9A (0.33) RORCSCN9AEIF2AK4BTKKIF18A
SCHEMBL29464304 0.91 SCN9A (0.33) RORCSCN9AEIF2AK4BTKKIF18A
SCHEMBL19951386 0.91 SCN9A (0.33) RORCSCN9AEIF2AK4BTKKIF18A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109641873-B N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use for the treatment of disease 诺华股份有限公司 2022-03-18 CN disclosed